Literature DB >> 15742464

Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.

Charles A Dinarello1.   

Abstract

This review examines the differences in the incidence, spectrum, and mechanisms of activation of opportunistic infections, such as Mycobacterium tuberculosis, in patients with rheumatic diseases treated with the soluble TNF p75 receptor etanercept compared to the 2 anti-TNF-alpha monoclonal antibodies, infliximab and adalimumab.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15742464

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN： 0380-0903


  23 in total

Review 1.  Immunosuppression related to collagen-vascular disease or its treatment.

Authors:  Carol Dukes Hamilton
Journal:  Proc Am Thorac Soc       Date:  2005

2.  Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.

Authors:  Mohammad Fallahi-Sichani; JoAnne L Flynn; Jennifer J Linderman; Denise E Kirschner
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

3.  Intra-articular transplantation of atsttrin-transduced mesenchymal stem cells ameliorate osteoarthritis development.

Authors:  Qingqing Xia; Shouan Zhu; Yan Wu; Jiaqiu Wang; Youzhi Cai; Pengfei Chen; Jie Li; Boon Chin Heng; Hong Wei Ouyang; Ping Lu
Journal:  Stem Cells Transl Med       Date:  2015-03-30       Impact factor: 6.940

4.  Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation.

Authors:  François Maignen; Manfred Hauben; Panos Tsintis
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

5.  Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

Authors:  Antonio Furlan; Valmen Monzani; Leonid L Reznikov; Flavio Leoni; Gianluca Fossati; Daniela Modena; Paolo Mascagni; Charles A Dinarello
Journal:  Mol Med       Date:  2011-02-22       Impact factor: 6.354

6.  Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Authors:  Charles A Dinarello; Gianluca Fossati; Paolo Mascagni
Journal:  Mol Med       Date:  2011-05-05       Impact factor: 6.354

7.  Novel biological therapies for inflammatory bowel disease.

Authors:  Pieter C F Stokkers; Daniel W Hommes
Journal:  Curr Treat Options Gastroenterol       Date:  2006-06

8.  Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.

Authors:  Mohammed F Shamji; Priscilla Hwang; Robert W Bullock; Samuel B Adams; Dana L Nettles; Lori A Setton
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2009-07       Impact factor: 3.368

9.  Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.

Authors:  Heiko Bruns; Christoph Meinken; Philipp Schauenberg; Georg Härter; Peter Kern; Robert L Modlin; Christian Antoni; Steffen Stenger
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

10.  Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.

Authors:  Elizabeth A Miller; Joel D Ernst
Journal:  J Clin Invest       Date:  2009-05       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.